GlassScriptPhysician profile
Kamal Khalafi
NPI 1992791263
$16,330.62
in general payments reported to CMS, 2019-2025
50 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,245 · 2020: $1,954 · 2021: $2,561 · 2022: $2,764 · 2023: $2,920 · 2024: $601 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.98 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,384.91 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,463.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,089.92 | 2020-2023 | |
| Pfizer INC. | $1,065.88 | 2019-2023 | |
| Novo Nordisk INC | $890.56 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $843.48 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $630.02 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $514.47 | 2019-2023 | Trulicity, Baqsimi, Jardiance |
| Janssen Pharmaceuticals, INC | $491.68 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $442.62 | 2019-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.30 | 2019-2024 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $411.97 | 2019-2024 | |
| Astellas Pharma US INC | $357.63 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $259.60 | 2020-2023 | Xifaxan |
| Amgen INC. | $254.74 | 2019-2024 | Repatha |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Khalafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.